MED13
protein-codingmediator complex subunit 13, the group of Mediator complex
Gene summary
This gene encodes a component of the mediator complex (also known as TRAP, SMCC, DRIP, or ARC), a transcriptional coactivator complex thought to be required for the expression of almost all genes. The mediator complex is recruited by transcriptional activators or nuclear receptors to induce gene expression, possibly by interacting with RNA polymerase II and promoting the formation of a transcriptional pre-initiation complex. The product of this gene is proposed to form a sub-complex with MED12, cyclin C, and CDK8 that can negatively regulate transactivation by mediator. [provided by RefSeq, Jul 2008]
- THRAP1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~122.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0032485
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0032485
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0032485
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0032485
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0000508
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0100038
Submitter: ClinGen
*MED13* was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2018 (Snijders Blok et al., PMID: 29740699). The disorder is characterised by global developmental delay apparent in infancy with mildly impaired intellectual development, expressive speech delay, behavioural abnormalities (including autism spectrum disorder or attention deficit-hyperactivity disorder), nonspecific dysmorphic features, obstipation, ocular anomalies, and poor overall growth (PMID: 29740699). Fourteen variants (nonsense, frameshift, missense and in-frame indel) that have been reported in 15 probands in five publications are included in this curation (PMIDs: 25363768, 28263302, 29740699, 33258286, 33931951). More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity is loss of function. In summary, there is definitive evidence supporting the relationship between *MED13* and autosomal dominant complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on May 17, 2022 (SOP Version 9).
Inheritance Pattern: AD
Disease ID:MONDO:0032485
Submitter: Illumina
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to MED13 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005121.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 5 | 51 | 5 | 61 | ||
| missense | 2 | 16 | 494 | 95 | 7 | 614 |
| nonsense | 15 | 8 | 4 | 27 | ||
| start loss | 0 | |||||
| frameshift | 20 | 17 | 3 | 40 | ||
| splice donor/acceptor (+/-2bp) | 6 | 4 | 7 | 17 | ||
| Total | 43 | 45 | 513 | 146 | 12 | 759 |
Highest pathogenic variant AF is 0.0000013790459
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005112.2 | 30 | MANE Select | |
| Ensembl | ENSP00000380888.2 | 30 | MANE Select | |
| Ensembl | ENSP00000464131.1 | 3 | Standard | |
| Ensembl | ENSP00000604786.1 | 29 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| med13b | Danio rerio | Structure: cranial neural crest cell Quality: mislocalised abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Thyroid hormone signaling pathway - Homo sapiens (human)
- Developmental Biology
- Gene expression (Transcription)
- Generic Transcription Pathway
- RNA Polymerase II Transcription
Biological Process
- regulation of transcription by RNA polymerase II
- transcription initiation from RNA polymerase II promoter
- intracellular steroid hormone receptor signaling pathway
- androgen receptor signaling pathway
- cholesterol homeostasis
Molecular Function
- transcription coregulator activity
- transcription coactivator activity
- nuclear receptor transcription coactivator activity
- signaling receptor activity
- vitamin D receptor binding
Cellular Component
- nucleus
- nucleoplasm
- membrane
- mediator complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000397786
- Coding exons
- 30
- Length
- 122678
- Individuals with no LoFs
- 124782
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 3
- Defined
- 124785
- p
- 0.0000120
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.62 | 871 | 1.12e+3 | 0.779 | 0.0000556 | 14195 |
| Missense (PolyPhen) | 314 | 529.75 | 0.59273 | 6708 | ||
| Synonymous | -1.38 | 422 | 388 | 1.09 | 0.0000191 | 4248 |
| Loss of Function | 9.19 | 0 | 98.4 | 0.00 | 0.00000492 | 1257 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.000093 | 0.000093 | rare |
| European (Non-Finnish) | 0.0000089 | 0.0000088 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. {ECO:0000269|PubMed:16595664}.;
Recessive Scores
- pRec
- 0.134
Intolerance Scores
- LoFtool
- 0.0136
- RVIS EVS
- -1.43
- RVIS percentile EVS
- 4.05
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.692
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |